AGC Biologics begins construction of new facility in Denmark
Venture anticipated to more than double single-use bioreactor mammalian cell-culture capacity on site
AGC Biologics, a contract development and manufacturing organization (CDMO), has broken ground at its new facility at its Copenhagen, Denmark site, which will allow the company to increase its capacity and space to accommodate new and current clients’ needs.
The multipurpose facility will consist of a manufacturing building, an office building and a visitors’ center. The manufacturing structure will feature four levels holding over 86,000 square feet spread across manufacturing, quality control laboratories, technical and warehouse spaces. Production will be based on genetically modified organisms, biosafety level 1, manufactured with single-use technology in clean rooms.
This investment is expected to more than double AGC Biologics’ single-use bioreactor mammalian cell-culture capacity in Copenhagen. An expected completion date is yet to be determined.
The company also recently made headlines after purchasing a 622,000 square-foot cell and gene therapy facility in Longmont, CO.
